Indication and Limitation of Use

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13)… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination with FOLFOX, as monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.

Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.

×
×

You are now leaving Vectibix.com

Please know that the sponsors of this site are not responsible for content on the site you are about to enter.

Cancel
Continue

Support organizations with resources for your patients with mCRC

  • Chris4Life

  • Colon Cancer Alliance

  • Fight Colorectal Cancer

  • Cancer Support Community

  • Patient Advocate Foundation


Patient counseling information

Patients should be advised of a few things when being prescribed Vectibix®:1

  • Periodic monitoring of electrolytes1
  • Limiting sun exposure (use sunscreen, wear hats) while receiving Vectibix® and for 2 months after the last dose of Vectibix® therapy1
  • Using adequate contraception in both males and females while receiving Vectibix® and for 6 months after the last dose of Vectibix® therapy1

Patients may experience side effects when taking Vectibix®. Advise patients to contact a healthcare professional if they experience any of the following:1

  • Skin and ocular/visual changes1
  • Signs and symptoms of infusion reactions, including fever, chills, or breathing problems1
  • Diarrhea and dehydration1
  • Persistent or recurrent coughing, wheezing, dyspnea, or new-onset facial swelling1
  • Pregnancy or nursing1

Site Map
×